{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:12:56Z","timestamp":1792026776348,"version":"4.4.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":967,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Although the haemodynamic effects of angiotensin receptor-neprilysin inhibitor (ARNI) on patients with heart failure have been demonstrated, the effect on glucose metabolism has not been fully elucidated. We retrospectively investigated the effect of ARNI on abnormal glucose metabolism in patients with stable chronic heart failure using an additional structural equation model (SEM) analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed 34 patients who regularly visited to the outpatient department of our institute with heart failure from October 2021 and July 2022 and who were taking angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Seventeen patients switched from ACE inhibitors or ARBs to an ARNI (ARNI group), and the other 17 patients continued treatment with ACE inhibitors or ARBs (control group).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, although the ARNI group included fewer patients with heart failure with preserved ejection fraction in comparison with the control group (P = 0.004), patients with heart failure with mildly reduced ejection fraction, and heart failure with reduced ejection fraction were mostly biased towards the ARNI group (although not statistically significant). The baseline insulin resistance in the ARNI group was already significantly higher in comparison with the control group [fasting blood insulin, 9.7 (7.4, 11.6) vs. 7.8 (5.2, 9.2) \u03bcU\/mL, P = 0.033; homoeostasis model assessment of insulin resistance (HOMA-IR), 3.10 (1.95, 4.19) vs. 2.02 (1.56, 2.42), P = 0.014].<\/jats:p>\n                    <jats:p>Three months later, the fasting blood insulin and the HOMA-IR levels were both found to have decreased in comparison with the baseline values [baseline to 3 months: insulin, 9.7 (7.4, 11.6) to 7.3 (4.6, 9.4) \u03bcU\/mL, P &amp;lt; 0.001; HOMA-IR, 3.10 (1.95, 4.19) to 1.96 (1.23, 3.09), P &amp;lt; 0.001]. An additional SEM analysis demonstrated that the initiation of ARNI had caused a reduction in the fasting blood insulin and the HOMA-IR levels at 3 months independently of the baseline fasting blood insulin and HOMA-IR levels, respectively. Similarly, the initiation of ARNI resulted in a significant reduction in serum uric acid levels (6.28 \u00b1 0.35 to 5.80 \u00b1 0.30 mg\/dL, P = 0.008).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In conclusion, even in a short period of only 3 months, the administration of ARNI improved insulin resistance and consequently reduced the serum uric acid levels in patients with stable chronic heart failure. Although the ARNI group already had high insulin resistance at baseline, an additional SEM analysis revealed that the decreased insulin resistance was truly due to the effect of ARNI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14352","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T04:07:31Z","timestamp":1679371651000},"page":"1860-1870","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effects of Angiotensin Receptor-Neprilysin Inhibitor on Insulin Resistance in Patients with Heart Failure"],"prefix":"10.1093","volume":"10","author":[{"given":"Yusuke","family":"Kashiwagi","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Nagoshi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Kimura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Oi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kawai","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"2026012114103874400_ehf214352-bib-0001","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"2026012114103874400_ehf214352-bib-0002","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the losartan heart failure survival study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"2026012114103874400_ehf214352-bib-0003","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012114103874400_ehf214352-bib-0004","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","article-title":"Heart failure drug treatment: the fantastic four","volume":"42","author":"Bauersachs","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114103874400_ehf214352-bib-0005","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of Change in N-terminal pro-B-type natriuretic peptide following initiation of Sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"2026012114103874400_ehf214352-bib-0006","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s00392-019-01440-y","article-title":"Sacubitril\/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction","volume":"108","author":"Martens","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2026012114103874400_ehf214352-bib-0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110596","article-title":"The role of sacubitril\/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: from clinical trials to real-world settings","volume":"130","author":"Mazza","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"2026012114103874400_ehf214352-bib-0008","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026012114103874400_ehf214352-bib-0009","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12933-022-01545-1","article-title":"Effects of sacubitril\/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials","volume":"21","author":"Wijkman","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2026012114103874400_ehf214352-bib-0010","article-title":"Heart failure treatments such as angiotensin receptor\/neprilysin inhibitor improve heart failure status and glucose metabolism","volume":"14","author":"Kashiwagi","year":"2022","journal-title":"Cureus"},{"key":"2026012114103874400_ehf214352-bib-0011","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0002-9343(02)01530-9","article-title":"Functional class in patients with heart failure is associated with the development of diabetes","volume":"114","author":"Tenenbaum","year":"2003","journal-title":"Am J Med"},{"key":"2026012114103874400_ehf214352-bib-0012","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0735-1097(97)00185-X","article-title":"Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure","volume":"30","author":"Swan","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2026012114103874400_ehf214352-bib-0013","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12933-021-01348-w","article-title":"Triglyceride-rich lipoprotein and LDL particle subfractions and their association with incident type 2 diabetes: the PREVEND study","volume":"20","author":"Sokooti","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026012114103874400_ehf214352-bib-0014","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.amjcard.2006.10.068","article-title":"Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials)","volume":"99","author":"Andraws","year":"2007","journal-title":"Am J Cardiol"},{"key":"2026012114103874400_ehf214352-bib-0015","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/00004872-200018110-00011","article-title":"The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats","volume":"18","author":"Togashi","year":"2000","journal-title":"J Hypertens"},{"key":"2026012114103874400_ehf214352-bib-0016","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/01.HYP.0000078490.59735.6E","article-title":"Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension","volume":"42","author":"Furuhashi","year":"2003","journal-title":"Hypertension"},{"key":"2026012114103874400_ehf214352-bib-0017","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.metabol.2015.09.019","article-title":"The impact of an inverse correlation between plasma B-type natriuretic peptide levels and insulin resistance on the diabetic condition in patients with heart failure","volume":"65","author":"Inoue","year":"2016","journal-title":"Metabolism"},{"key":"2026012114103874400_ehf214352-bib-0018","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-96970-9","article-title":"Treatment with atrial natriuretic peptide induces adipose tissue browning and exerts thermogenic actions in vivo","volume":"11","author":"Kimura","year":"2021","journal-title":"Sci Rep"},{"key":"2026012114103874400_ehf214352-bib-0019","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158373","article-title":"Exogenous ANP treatment ameliorates myocardial insulin resistance and protects against ischemia-reperfusion injury in diet-induced obesity","volume":"23","author":"Oi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026012114103874400_ehf214352-bib-0020","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ejhf.1056","article-title":"Sacubitril\/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF","volume":"20","author":"Mogensen","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012114103874400_ehf214352-bib-0021","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1002\/ejhf.1984","article-title":"Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF","volume":"22","author":"Selvaraj","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114103874400_ehf214352-bib-0022","doi-asserted-by":"crossref","first-page":"F826","DOI":"10.1152\/ajprenal.00012.2017","article-title":"Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2","volume":"313","author":"Toyoki","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026012114103874400_ehf214352-bib-0023","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1559827615601973","article-title":"Nonpharmacological management of gout and hyperuricemia: hints for better lifestyle","volume":"11","author":"Kakutani-Hatayama","year":"2017","journal-title":"Am J Lifestyle Med"},{"key":"2026012114103874400_ehf214352-bib-0024","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1161\/ATVBAHA.117.309128","article-title":"Uric acid is associated with inflammatory biomarkers and induces inflammation via activating the NF-\u03baB signaling pathway in HepG2 cells","volume":"37","author":"Spiga","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026012114103874400_ehf214352-bib-0025","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.2337\/db10-0916","article-title":"Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome","volume":"60","author":"Baldwin","year":"2011","journal-title":"Diabetes"},{"key":"2026012114103874400_ehf214352-bib-0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101411","article-title":"URAT1-selective inhibition ameliorates insulin resistance by attenuating diet-induced hepatic steatosis and brown adipose tissue whitening in mice","volume":"55","author":"Tanaka","year":"2022","journal-title":"Mol Metab"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.14352","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.14352","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/3\/1860\/65017817\/eschf_10_3_1860.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/3\/1860\/65017817\/eschf_10_3_1860.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:11:51Z","timestamp":1769022711000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/3\/1860\/8304709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,21]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14352","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,3,21]]},"assertion":[{"value":"2022-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}